Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.38 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448813 | 1.00 | CYP17A1 (0.44) | CYP17A1AAK1RXFP1KCNQ4KCNQ5 | |
| SCHEMBL14725520 | 0.87 | CYP17A1 (0.48) | CYP17A1AAK1RXFP1KCNQ4KCNQ5 | |
| SCHEMBL12519275 | 0.87 | AAK1 (0.44) | CYP17A1AAK1RXFP1KCNQ4KCNQ5 | |
| SCHEMBL21949209 | 0.85 | AAK1 (0.43) | CYP17A1AAK1LMNA | |
| SCHEMBL23750699 | 0.84 | AAK1 (0.42) | CYP17A1AAK1RXFP1KCNQ4KCNQ5 | |
| SCHEMBL197226 | 0.83 | AAK1 (0.43) | CYP17A1AAK1RXFP1KCNQ4KCNQ5 | |
| SCHEMBL26405293 | 0.81 | CYP17A1 (0.41) | CYP17A1AAK1RXFP1KCNQ4KCNQ5 | |
| SCHEMBL29697261 | 0.81 | CYP17A1 (0.44) | CYP17A1RXFP1KCNQ4KCNQ5BRAF | |
| SCHEMBL22990771 | 0.81 | CYP17A1 (0.44) | CYP17A1RXFP1KCNQ4KCNQ5BRAF | |
| SCHEMBL2833050 | 0.80 | CYP17A1 (0.52) | CYP17A1AAK1RXFP1KCNQ4KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3036231-B1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | JUBILANT BIOSYS LTD (IN) | 2020-02-26 | — | — | EP | disclosed |
| US-10273224-B2 | Substituted pyrimidine compounds, compositions and medicinal applications thereof | JUBILANT BIOSYS LIMITED (IN) | 2019-04-30 | — | — | US | disclosed |
| CN-109071543-A | Inhibit the pyridine derivate of RAF kinases and vascular endothelial growth factor receptor, preparation method contains its medical composition and its use | 三进制药株式会社 | 2018-12-21 | — | — | CN | disclosed |
| US-20160207905-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2016-07-21 | — | — | US | disclosed |
| US-20160207905-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2016-07-21 | — | — | US | disclosed |
| WO-2015025197-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | JUBILANT BIOSYS LIMITED (IN) | 2015-02-26 | — | — | WO | disclosed |
| US-20130005760-A1 | HETEROCYCLIC COMPOUND HAVING AZOLE GROUP | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-01-03 | — | — | US | disclosed |
| EP-0897919-B1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMA CO LTD (JP) | 2004-06-16 | — | — | EP | disclosed |
| EP-0787720-B1 | PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT | WAKUNAGA SEIYAKU KK (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-6211375-B1 | IMPROVED INTESTINAL ABSORPTION | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-03 | — | — | US | disclosed |
| US-5910498-A | NOVEL COMPOUNDS HAVING REDUCED CYTOTOXICITY, PHOTOTOXICITY; TREATING BACTERIAL AND VIRAL INFECTIONS | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1999-06-08 | — | — | US | disclosed |
| EP-0897919-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-02-24 | — | — | EP | disclosed |
| EP-0787720-A1 | NOVEL PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005760-A1 | HETEROCYCLIC COMPOUND HAVING AZOLE GROUP | PRMT7, PRMT1, ZC3HAV1 | CYP17A1 1890/4885AAK1 4000/4885RXFP1 1582/4885 |
| US-20160207905-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | TYMP, EGFR, TK1 | CYP17A1 2353/4885AAK1 803/4885RXFP1 4178/4885 |
| US-10273224-B2 | Substituted pyrimidine compounds, compositions and medicinal applications thereof | TYMP, EGFR, TK1 | CYP17A1 2353/4885AAK1 803/4885RXFP1 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.